Research Device – Talk Bio

Acrivon Therapeutics Showcases AP3 Platform and Preclinical Data for ACR-2316 with Three Poster Presentations at AACR-NCI-EORTC 2025

3 days ago talkbio0Tagged ACR-2316, Acrivon, AP3, Conferences, Generative Phosphoproteomics, Inhibitor, KaiSR, partial response, PKMYT1 protein, human, Platform, PLK1 gene, precision oncology, preclinical data, Study models, WEE1 inhibitor

Acrivon Therapeutics; AP3 platform; Generative Phosphoproteomics; KaiSR model; ACR-2316; AACR-NCI-EORTC conference; preclinical data; partial response; WEE1 inhibitor; PKMYT1 inhibitor; PLK1; precision oncology

Meeting on the Mesa 2025 Arrives Amid Mixed Signals for Cell and Gene Therapy Sector

3 weeks ago talkbio0Tagged Advanced therapies, Alternative, Cells, Clinical Trials, commercialization, Gene Modification, gene therapy, Industry, meeting, MESA, partnerships, payment, Phoenix Arizona, regulatory challenges, RNA, Messenger, Study models

Cell and gene therapy; Meeting on the Mesa; Commercialization; Clinical trials; Advanced therapies; Industry partnerships; Regulatory challenges; Phoenix Arizona; mRNA; Gene editing; Alternative payment models

Exclusive: Roivant-backed VantAI debuts AI model Neo-1, taking the big next step after AlphaFold 3

7 months ago talkbio0Tagged molecular glues, Neo-1, Study models

Neo-1, Study models, molecular glues

Hospital Group Seeks to Intervene in Lawsuit Against Lilly’s 340B Rebate Model

9 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, hospital intervention, Study models, United States Health Resources and Services Administration

340B Drug Pricing Program, Eli Lilly, rebate model, lawsuit, hospital intervention, Health Resources and Services Administration (HRSA), drug pricing

Dual Hormone Therapies Normalize Sleep Patterns in ALS Mouse Models

9 months ago talkbio0Tagged Amyotrophic Lateral Sclerosis, Architecture, House mice, melanin-concentrating hormone, orexins, Sleep, Sleep disturbances, Study models, suvorexant

Amyotrophic lateral sclerosis (ALS), sleep disturbances, orexin antagonist, melanin-concentrating hormone (MCH), suvorexant, sleep architecture, mouse models

Bioptimus Secures $76M Funding to Develop Revolutionary AI Foundation Model for Biology

9 months ago talkbio0Tagged Alanine Transaminase, Artificial Intelligence, biology (field), Bioptimus, Cathay Innovation, Drug Industry, medical innovation, Study models

Bioptimus, AI foundation model, biology, funding, Cathay Innovation, GPT of biology, biological research, pharmaceutical industry, biotech, medical innovation.

Eli Lilly and Johnson & Johnson Sue US Government Over 340B Rebate Models

11 months ago talkbio0Tagged Drug Pricing Program, Eli, Eli Lilly, healthcare litigation, HRSA, Johnson & Johnson, pharmaceutical pricing, rebate, Study models

340B Drug Pricing Program, Eli Lilly, Johnson & Johnson, HRSA, rebate models, pharmaceutical pricing, healthcare litigation

AbbVie Expands CNS Capabilities with $1.4 Billion Acquisition of Aliada Therapeutics

12 months ago talkbio0Tagged AbbVie, ALIA-1758, Aliada, Alzheimer 's disease, anti-amyloid, asset, Blood - brain barrier anatomy, CNS disorder, pharmaceutical acquisition, Study models, Technology

AbbVie, Aliada Therapeutics, CNS diseases, Alzheimer’s disease, anti-amyloid asset, blood-brain barrier technology, MODEL platform, ALIA-1758, pharmaceutical acquisition

Johnson & Johnson Abandons 340B Rebate Plan Following HRSA Pressure and Congressional Advocacy

1 year ago talkbio0Tagged Dosage Forms, drug discount program, Health Policy, HRSA, Johnson & Johnson, Study models

340B drug discount program, Johnson & Johnson, HRSA, rebate model, healthcare policy, pharmaceutical pricing

Biden Ramps Up Fight Against High Drug Prices in State of the Union Address

2 years ago talkbio0Tagged Addresses (publication format), Biden administration, Big Pharma, Commercial Drug Sales, drug price, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private insurance, Protections, Study models, Union

State of the Union Address, Biden Administration, Big Pharma, Drug Prices, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private Insurance Protections, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy Access Model, Commercial Drug Sales Rebates